Since the first report of induced pluripotent stem cells (iPSCs) by Yamanaka in 2006 (Takahashi and Yamanaka, 2006) , the stem cell world has entered the reprogramming period. We witnessed rapid developments at breathtaking speed ranging from germline competent iPSCs in mice, iPSCs from human both normal and diseased (Takahashi et al., 2007; Yamanaka, 2007; Yu et al., 2007) to iPSCs from rats Liao et al., 2009) , monkey (Liu et al., 2008) and pigs (Esteban et al., 2009; Wu et al., 2009) . The magic of iPS has fascinated seasoned investigators as well as new comers in and outside the stem cell field (Pei, 2009) . As the iPS momentum builds around the world, few pause to think about the difference between assumption and reality about the pluripotency of iPSCs. Recently, two groups, both from China, not only paused to think about this, but also proved beyond any doubt that some of the iPSCs generated from mice are truly as pluripotent as embryonic stem (ES) cells (Kang et al., 2009; Zhao et al., 2009) .
Pluripotency refers to the ability of stem cells to generate all the cell lineages except trophectoderm, a property possessed only by cells from the inner cell mass (ICM) of blastocysts in vivo (Pan et al., 2002) . Since the derivation of embryonic stem cells, a series of experimental approaches were developed to evaluate pluripotency, from in vitro differentiation into various tissue or cell lineages or embryonic body formation, teratoma formation in immune-compromised mice, generation of chimera, chimera competent for germline transmission and the most stringent test-tetraploid complementation (Maherali and Hochedlinger, 2008) . Despite the fact that ES cells have been generated from mouse, rat, monkey and human, only those from mouse have met the most stringent test, i.e. live pups born by injecting mouse ES cells into tetraploid blastocysts whose own ICM cannot contribute to the development of the embryos (Figure 1) . Prior to the two reports mentioned above, mouse iPSCs have been shown to meet all the pluripotency tests including tetraploid complementation that generated embryos viable to late stages of gestation, but no live pups were born Wernig et al., 2007; Kim et al., 2008) . So, it is widely assumed and accepted that those mouse iPSCs are pluripotent, even in the absence of evidence for live pups from tetraploid complementation.
The groups of Zhou and Zeng, from the Institute of Zoology in Beijing and Shanghai Jiaotong University, respectively, used an improved iPS protocol to generate 37 iPSC lines (Zhao et al., 2009) . Through elegant tetraploid manipulations, they were able to produce a total of 27 live pups from three iPSC lines (Zhao et al., 2009) . They noted that only iPSCs isolated at Day 14, not those from Days 20 and 36 can generate live pups, perhaps, reflecting the reprogramming states of these cells. More remarkably, the success rate for tetraploid complementation is comparable between ES cells and iPSCs (3%) (Zhao et al., 2009) . The Gao group from National Institute of Biological Sciences in Beijing took another route, using a doxycycline controlled expression system to induce iPSCs (Kang et al., 2009) . One live pup survived to healthy adulthood, which is sufficient to prove the pluripotency of the iPSCs generated by the inducible system (Kang et al., 2009) . Both reports confirmed each other, proved that the iPS technology is as potent as we have originally imaged, i.e. to be able to generate fully pluripotent stem cells. This achievement caps the debate on the choice between iPS and somatic cell nuclear transfer or therapeutical cloning for regenerative medicine. As new methods are continuing to emerge to perfect the iPS technology, we are at the dawn of a new era that novel therapies may be developed directly or indirectly through disease models based on pluripotent stem cells, mostly iPSCs.
The take-home message for this exciting story may be the following: never assume anything.
